Let’s celebrate! We are thrilled to share a monumental milestone with you: OMF StudyME Registry has now surpassed 10,000 participants!
In April 2023, we proudly launched OMF StudyME, a participant registry powered by StudyPages. This innovative recruitment tool was created to bridge the gap between individuals living with ME/CFS, Long COVID, and related diseases, and the researchers dedicated to understanding and finding effective treatments for these diseases.
Today, we have over 10,000 participants, a testament to the collective effort and commitment of our community. This achievement addresses one of the most common challenges researchers face: finding participants for their studies. OMF StudyME Registry was designed to address this challenge by providing a free global participant registry that connects researchers with individuals eager to contribute to research on ME/CFS, Long COVID, and related diseases.
This incredible achievement wouldn’t have been possible without the support and dedication of our community. If you haven’t already done so, by signing up, you have the power to help researchers find answers for ME/CFS and Long COVID. The process is easy and takes less than five minutes.
Key Insights About StudyME
OMF StudyME has registered over 10,000 participants across 61 countries, highlighting the global urgency for research in this field.
We have already helped recruit for ten studies at:
- Stanford University
- Bateman Horne Center
- Scripps Research
- Autoimmune Registry
- Mt Sinai
- Nova Southeastern University
- Vassar College
The demographic data reveals a pronounced sex disparity with a notable 5:1 ratio of female to male participants, primarily aged 25 – 55.
Preliminary insights from the registry highlight the profound impacts of these conditions on everyday life. Participants have indicated that they are interested in research in the following areas:
- Impairment in carrying out everyday activities (87%)
- Post-exertional malaise (85%)
- Cognitive impairment or brain fog (81%)
- Unrefreshing sleep (77%)
- Exertion intolerance (76%)
Thank you for your continued support and commitment to advancing research for ME/CFS and Long COVID, and related diseases.
